Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $200 Price Target

Author: Benzinga Newsdesk | May 02, 2024 02:41pm
Needham analyst Joseph Stringer reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $200 price target.

Posted In: ALNY